In a report released yesterday, Terence Flynn from Morgan Stanley maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report), ...
Morgan Stanley lowered the firm’s price target on Crispr Therapeutics (CRSP) to $30 from $45 and keeps an Underweight rating on the shares. The ...
DeepSeek was tasked with selecting two stocks investors can buy now and hold long-term due to their growth potential.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback